Citigroup Inc Citius Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 15,940 shares of CTXR stock, worth $41,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,940

Previous 17,998 11.43%

Holding current value

$41,284

Previous $10,000 30.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.48 - $1.02 $987 - $2,099	-2,058 Reduced 11.43%	15,940 $7,000
Q2 2024 Aug 12, 2024	SELL	$0.58 - $1.03 $4,001 - $7,107	-6,900 Reduced 27.71%	17,998 $10,000
Q1 2024 May 10, 2024	BUY	$0.6 - $0.9 $4,322 - $6,483	7,204 Added 40.71%	24,898 $22,000
Q4 2023 Feb 09, 2024	BUY	$0.65 - $0.86 $11,460 - $15,163	17,632 Added 28438.71%	17,694 $13,000
Q3 2023 Nov 09, 2023	SELL	$0.65 - $1.25 $23,749 - $45,672	-36,538 Reduced 99.83%	62 $0
Q2 2023 Aug 10, 2023	SELL	$1.08 - $1.65 $35,454 - $54,166	-32,828 Reduced 47.28%	36,600 $43,000
Q1 2023 May 11, 2023	BUY	$0.78 - $1.42 $54,153 - $98,587	69,428 New	69,428 $81,000
Q2 2022 Aug 10, 2022	SELL	$0.88 - $1.87 $8,565 - $18,200	-9,733 Reduced 89.83%	1,102 $1,000
Q1 2022 May 12, 2022	SELL	$1.38 - $1.89 $24,811 - $33,980	-17,979 Reduced 62.4%	10,835 $19,000
Q4 2021 Feb 10, 2022	BUY	$1.51 - $2.2 $23,368 - $34,047	15,476 Added 116.03%	28,814 $44,000
Q3 2021 Nov 10, 2021	BUY	$1.74 - $2.6 $23,208 - $34,678	13,338 New	13,338 $27,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

23.7M

Call Options Held

83.1K

Put Options Held

32.1K

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $378M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account